Stiris Research Inc. Announces Award of Proof-Of-Concept Study for Agitation in Autism Spectrum Disorder

London, ON — October 2021 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the awarding of a proof-of-concept study for the acute treatment of agitation in adolescents with Autism Spectrum Disorder.

“We are thrilled to have the opportunity to work on this proof-of-concept study. Pediatric and Adolescent research is always a rewarding area to do research in and we look forward to working on treatments for acute agitation as it relates to their ASD” Amanda Carrera, Vice President.

Autism spectrum disorder is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The disorder also includes limited and repetitive patterns of behavior. The term “spectrum” in autism spectrum disorder refers to the wide range of symptoms and severity. (

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.